WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H563439
CAS#: 435327-40-5
Description: Avasopasem manganese, also known as GC-4419; M 40419 and SC-72325A, is a superoxide dismutase mimetic drug candidate. GC4419 increases cancer cell killing with sensitization to ionizing radiation while protecting normal cells. GC4419 Enhances the Oxidation of Pharmacological Ascorbate and Its Anticancer Effects in an H₂O₂-Dependent Manner.
Hodoodo Cat#: H563439
Name: Avasopasem manganese
CAS#: 435327-40-5
Chemical Formula: C21H35Cl2MnN5
Exact Mass: 0.00
Molecular Weight: 483.380
Elemental Analysis: C, 52.18; H, 7.30; Cl, 14.67; Mn, 11.37; N, 14.49
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Avasopasem manganese; GC-4419; GC4419; GC 4419; M 40419; M40419; M-40419; SC 72325A; SC-72325A; SC72325A;
IUPAC/Chemical Name: (PBPY-7-11-2344'3')-dichlorido[(11S,12S,71S,72S)-2,6,8,11-tetraaza-4(2,6)-pyridina-1,7(1,2)-dicyclohexanacycloundecaphane-κ5N2,N1.4,N6,N8,N11]manganese
InChi Key: WXEMWBBXVXHEPU-NDOCQCNASA-L
InChi Code: InChI=1S/C21H35N5.2ClH.Mn/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20;;;/h5-7,18-25H,1-4,8-15H2;2*1H;/q;;;+2/p-2/t18-,19-,20-,21-;;;/m0.../s1
SMILES Code: Cl[Mn-5]1234(Cl)[N@@H+]([C@H]5CCCC[C@@H]5[N@H+]2CC6=CC=CC7=[N+]63)CC[N@@H+]1[C@@H]8[C@@H]([N@H+]4C7)CCCC8
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 483.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message
Sent On: Thu Nov 05 22:21:28 2020
Search: GC4419
11 selected items
PubMed Results
Items 1-11 of 11 (Display the 11 citations in PubMed)
1: Karlsson JOG, Jynge P, Ignarro LJ. May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients? Antioxidants (Basel). 2020 Oct 10;9(10):971. doi: 10.3390/antiox9100971. PMID: 33050459; PMCID: PMC7601469.
2: El-Mahdy MA, Alzarie YA, Hemann C, Badary OA, Nofal S, Zweier JL. The novel SOD mimetic GC4419 increases cancer cell killing with sensitization to ionizing radiation while protecting normal cells. Free Radic Biol Med. 2020 Jul 30;160:630-642. doi: 10.1016/j.freeradbiomed.2020.07.032. Epub ahead of print. PMID: 32739595.
3: Adamietz IA. Superoxiddismutasemimetikum (GC4419) vs. Placebo zur Reduktion von schweren oralen Mukositiden infolge simultaner Radiochemotherapie mit Cisplatin bei Kopf-Hals-Tumoren: randomisierte, doppelblinde Phase-IIb-Studie [A superoxide dismutase mimetic (GC4419) vs. placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer: a phase-IIb randomized double-blind study]. Strahlenther Onkol. 2020 Sep;196(9):834-836. German. doi: 10.1007/s00066-020-01639-3. PMID: 32561942.
4: Anderson CM, Lee CM, Saunders DP, Curtis A, Dunlap N, Nangia C, Lee AS, Gordon SM, Kovoor P, Arevalo-Araujo R, Bar-Ad V, Peddada A, Colvett K, Miller D, Jain AK, Wheeler J, Blakaj D, Bonomi M, Agarwala SS, Garg M, Worden F, Holmlund J, Brill JM, Downs M, Sonis ST, Katz S, Buatti JM. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer. J Clin Oncol. 2019 Dec 1;37(34):3256-3265. doi: 10.1200/JCO.19.01507. Epub 2019 Oct 16. Erratum in: J Clin Oncol. 2020 Jan 20;38(3):288. PMID: 31618127; PMCID: PMC6881100.
5: Mapuskar KA, Wen H, Holanda DG, Rastogi P, Steinbach E, Han R, Coleman MC, Attanasio M, Riley DP, Spitz DR, Allen BG, Zepeda-Orozco D. Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease. Redox Biol. 2019 Jan;20:98-106. doi: 10.1016/j.redox.2018.09.020. Epub 2018 Sep 27. PMID: 30296702; PMCID: PMC6174865.
6: Batinic-Haberle I, Tovmasyan A, Spasojevic I. Mn Porphyrin-Based Redox-Active Drugs: Differential Effects as Cancer Therapeutics and Protectors of Normal Tissue Against Oxidative Injury. Antioxid Redox Signal. 2018 Dec 1;29(16):1691-1724. doi: 10.1089/ars.2017.7453. Epub 2018 Aug 28. PMID: 29926755; PMCID: PMC6207162.
7: Oronsky B, Goyal S, Kim MM, Cabrales P, Lybeck M, Caroen S, Oronsky N, Burbano E, Carter C, Oronsky A. A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis. Transl Oncol. 2018 Jun;11(3):771-778. doi: 10.1016/j.tranon.2018.03.014. Epub 2018 Apr 23. PMID: 29698934; PMCID: PMC5918142.
8: Heer CD, Davis AB, Riffe DB, Wagner BA, Falls KC, Allen BG, Buettner GR, Beardsley RA, Riley DP, Spitz DR. Superoxide Dismutase Mimetic GC4419 Enhances the Oxidation of Pharmacological Ascorbate and Its Anticancer Effects in an H₂O₂-Dependent Manner. Antioxidants (Basel). 2018 Jan 19;7(1):18. doi: 10.3390/antiox7010018. PMID: 29351198; PMCID: PMC5789328.
9: Anderson CM, Sonis ST, Lee CM, Adkins D, Allen BG, Sun W, Agarwala SS, Venigalla ML, Chen Y, Zhen W, Mould DR, Holmlund JT, Brill JM, Buatti JM. Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):427-435. doi: 10.1016/j.ijrobp.2017.10.019. Epub 2017 Oct 16. PMID: 29174131; PMCID: PMC6430109.
10: Mapuskar KA, Flippo KH, Schoenfeld JD, Riley DP, Strack S, Hejleh TA, Furqan M, Monga V, Domann FE, Buatti JM, Goswami PC, Spitz DR, Allen BG. Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy. Cancer Res. 2017 Sep 15;77(18):5054-5067. doi: 10.1158/0008-5472.CAN-17-0106. Epub 2017 Aug 1. PMID: 28765155; PMCID: PMC5600863.
11: Cramer-Morales K, Heer CD, Mapuskar KA, Domann FE. SOD2 targeted gene editing by CRISPR/Cas9 yields Human cells devoid of MnSOD. Free Radic Biol Med. 2015 Dec;89:379-86. doi: 10.1016/j.freeradbiomed.2015.07.017. Epub 2015 Jul 21. PMID: 26208779; PMCID: PMC4890619.
